Skip to Content
Merck
CN
  • Intra-amniotic fluconazole therapy for Candida albicans intra-amniotic infection.

Intra-amniotic fluconazole therapy for Candida albicans intra-amniotic infection.

Obstetrics and gynecology (2013-02-01)
Lisa M Bean, Jessica R Jackson, William J Dobak, Timothy R Beiswenger, James A Thorp
ABSTRACT

The consequences of intra-amniotic Candida infection can be devastating. Currently, standard management includes delivery. We identified only one previous case reporting intrauterine antifungal therapy, which used transcervical amphotericin B. We present two cases of intra-amniotic Candida infection treated with intra-amniotic fluconazole instilled before membrane rupture. Two patients presented with intra-amniotic Candida albicans infection that was diagnosed during previability. Both underwent cerclage placement before culture results were available. Aggressive antifungal therapy was instituted using oral, vaginal, and intra-amniotic fluconazole instilled through serial amniocenteses. Both fetuses survived without sequelae. Intra-amniotic Candida infection is associated with preterm rupture of membranes, preterm labor, severe neonatal infection, and fetal death. Early diagnosis and treatment is essential.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Fluconazole, ≥98% (HPLC), powder
Supelco
Fluconazole, Pharmaceutical Secondary Standard; Certified Reference Material
Fluconazole, European Pharmacopoeia (EP) Reference Standard
Fluconazole for peak identification, European Pharmacopoeia (EP) Reference Standard